A panel of pharmacy experts explain what it means to provide quality oncology care for patients with myeloproliferative neoplasms (MPNs).

Drs Haumschild, Gilreath and Howe discuss the use of quality initiatives to support pharmacy accreditation through organizations such as URAC.

The pharmacist panel highlights valuable efforts to achieve URAC reaccreditation.

Drs Howe and Gilreath share key, specific considerations for quality initiatives for patients with MPNs.

Current care initiatives and opportunities to improve care for patients with MPNs are explored by Dr Howe.

The panel discusses aligning quality care initiatives with stakeholder considerations for MPN medications.

Highlighted are proposed solutions for current barriers to care for MPNs.

Pharmacy specialists illustrate the benefits of using a comprehensive team for care delivery to patients with MPNs.

Dr Haumschild leads a discussion about maximizing the impact of care through electronic medical record (EMR) utilization.

The panel offers effective practices to establish value-based and pathway-driven care for patients with MPNs.

Pharmacy experts detail their decision-making processes while selecting treatment for myeloproliferative neoplasms and monitoring patients on therapy.

Experts in MPN care discuss the importance and impact of patient education while managing myeloproliferative neoplasms.

Pharmacy specialists discuss quality initiatives in MPN management by sharing advice on assessing symptoms and patient adherence.

Drs Haumschild, Howe, and Gilreath contribute their final perspectives for maximizing care management between providers and patients with myeloproliferative neoplasms.